NEUBASE THERAPEUTICS INC's ticker is NBSE and the CUSIP is 64132K102. A total of 61 filers reported holding NEUBASE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.42 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $14 | -54.8% | 79,620 | 0.0% | 0.00% | -50.0% |
| Q4 2022 | $31 | -99.9% | 79,620 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $31,000 | -62.7% | 79,620 | 0.0% | 0.00% | -60.0% |
| Q2 2022 | $83,000 | -44.3% | 79,620 | 0.0% | 0.01% | -37.5% |
| Q1 2022 | $149,000 | +166.1% | 79,620 | +296.4% | 0.01% | +166.7% |
| Q4 2021 | $56,000 | -22.2% | 20,088 | 0.0% | 0.00% | -25.0% |
| Q3 2021 | $72,000 | -25.0% | 20,088 | 0.0% | 0.00% | -33.3% |
| Q2 2021 | $96,000 | – | 20,088 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 470,524 | $494,000 | 0.50% |
| CARNEGIE MELLON UNIVERSITY | 939,412 | $986,000 | 0.50% |
| CM Management, LLC | 370,000 | $389,000 | 0.41% |
| Decheng Capital Management III (Cayman), LLC | 1,000,000 | $1,050,000 | 0.40% |
| Sio Capital Management, LLC | 906,445 | $952,000 | 0.36% |
| AIGH Capital Management LLC | 1,027,585 | $1,079,000 | 0.28% |
| Greenlight Capital | 2,727,027 | $2,863,000 | 0.22% |
| Worth Venture Partners, LLC | 256,553 | $249,000 | 0.15% |
| PERKINS CAPITAL MANAGEMENT INC | 81,500 | $86,000 | 0.09% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 311,000 | $327,000 | 0.01% |